The first quarter of 2024 saw 115 agreed research and development partnerships totaling $36 billion. Eight of the top ten ranked by deal value involved technology platforms for developing a broad range of therapeutics, and three included Novartis as it expands its RNA and gene-based programs.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,